Research programme: cancer therapeutics - Rasna TherapeuticsAlternative Names: NPM1 programme
Latest Information Update: 26 Aug 2016
At a glance
- Originator Rasna Therapeutics
- Class Antineoplastics
- Mechanism of Action Enzyme inhibitors; Lysine specific demethylase 1 modulators; Nucleophosmin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 17 Aug 2016 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route)